This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Medicinova, Inc.. Active years: 2013-2014.
Company Filing History:
Years Active: 2013-2014
Title: Innovations by Inventor Kale Ruby
Introduction
Kale Ruby is an accomplished inventor located in Encinitas, California. He holds two patents that reflect his contributions to medical sciences, particularly in the field of pharmaceuticals. His innovative work primarily focuses on developing effective treatments for significant health conditions.
Latest Patents
One of Kale Ruby's notable patents is for Denibulin di-hydrochloride, also known as MN-029 di-hydrochloride (MN-029.2HCl). This potent vascular targeting agent has been recognized for its potential effectiveness in treating diseases that progress through the generation of neovasculature via angiogenesis. The invention emphasizes the synthesis and characterization of the di-hydrochloride salt MN-029 and explores the preparation of pharmaceutically acceptable formulations for its use.
Another significant patent involves methods and compositions for the treatment of irritable bowel syndrome. This method outlines a strategy for preventing and/or treating irritable bowel syndrome or alleviating symptoms associated with it. The approach includes administering an effective amount of a specific compound, indicating a targeted therapeutic pathway.
Career Highlights
Kale Ruby is affiliated with Medicinova, Inc., a company focused on developing innovative treatments for unmet medical needs. His role in this organization has enabled him to contribute significantly to research and development within the pharmaceutical industry.
Collaborations
While at Medicinova, he has collaborated with fellow professionals such as Kazuko Matsuda and Yuichi Iwaki. These collaborations have facilitated knowledge sharing and the exchange of innovative ideas that are crucial for advancing medical research.
Conclusion
Kale Ruby's advancements through his patents showcase his commitment to addressing challenging health issues. His work continues to influence the pharmaceutical landscape, and his collaborations enhance the potential for impactful medical solutions.